TICKERNERD
Menu
TMCITMCIHealthcare · Medical Devices

TMCI Stock Forecast: Treace Medical Concepts, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$3.88
−0.39% on the day

The 5 Wall Street analysts covering Treace Medical Concepts, Inc. hold a median 12-month price target of $5 — +29.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 8 Oct 2026 — in the upper half.

Market cap
$253.0M
Ticker Nerd rank
53 / 100
Median analyst target
$5.00
Analysts covering
5
Revenue$45.4M−4.2% y/y
Operating income−$15.0M
Net income−$15.9M
Free cash flow−$6.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.5%
1M
−16.3%
YTD
+58.2%
1Y
−37.1%
From 52W high
−44.2%
From 52W low
+222.9%
$1.20
$6.95
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TMCI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Treace Medical Concepts, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
53 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
85
Revisions
85
Size
65
Quality
60
Value
42
Issuance
33
Momentum
31
Growth
29
Volatility
15

Accruals (85): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (15): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TMCI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TMCI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00$7.00Jan 26Apr 26Jul 26Oct 26TMCIHigh $7.00Median $5.00Low $4.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
1 Buy3 Hold1 Sell
Low $4.50Median $5.00High $7.00

The green dot is the last close — the median target sits +29.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 Aug 2026Truist SecuritiesMaintainsHold$4.00 → $5.00
16 July 2026Truist SecuritiesMaintainsHold$2.00 → $4.00
16 July 2026Truist SecuritiesMaintainsHold—
2 Mar 2026Lake StreetMaintainsBuy—
7 Jan 2026StifelMaintainsHold—
18 Dec 2025Truist SecuritiesMaintainsHold—
10 Nov 2025Truist SecuritiesReiteratesHold—
7 Nov 2025BTIGDowngradeNeutral—
7 Nov 2025JP MorganDowngradeUnderweight—
7 Nov 2025UBSMaintainsNeutral—
15 Oct 2025Truist SecuritiesMaintainsHold—
4 Sept 2025Truist SecuritiesMaintainsHold—
8 Aug 2025StifelMaintainsHold—
8 Aug 2025UBSMaintainsNeutral—
9 May 2025UBSMaintainsNeutral—
11 Apr 2025Truist SecuritiesMaintainsHold—
13 Mar 2025Truist SecuritiesMaintainsHold—
3 Mar 2025Truist SecuritiesMaintainsHold—
31 Dec 2024Lake StreetInitiatesBuy—
18 Dec 2024Truist SecuritiesMaintainsHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TMCI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TMCI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Treace Medical Concepts, Inc. returned −37.1% against +16.2% for the S&P 500, dividends included.

TMCI vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26TMCIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TMCI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
5
Analysts cutting
0
Fundamentals

Treace Medical Concepts, Inc. (TMCI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.2×

Cheaper than 89% of US stocks

Price / sales
1.2×

Cheaper than 64% of US stocks

Price / book
3.7×

Cheaper than 26% of US stocks

EV / EBITDA
−6.2×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
−4.2%

Higher than 21% of US stocks

Earnings growth (YoY)
−4.2%

Higher than 31% of US stocks

Gross margin
78.5%

Higher than 90% of US stocks

Operating margin
−33.0%

Higher than 19% of US stocks

Net margin
−29.0%

Higher than 13% of US stocks

Returns & dividend
Return on equity
−72.0%

Higher than 17% of US stocks

Return on assets
−17.3%

Higher than 21% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Treace Medical Concepts, Inc. (TMCI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Treace Medical Concepts, Inc. has a market value of $253.0M and an enterprise value of $287.6M.

  • Revenue in the twelve months to 30 June 2026: $205.3M. The latest quarter shrank 4.2% year on year.

  • Net income over the same four quarters: −$59.5M, a −29.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.93.

  • Free cash flow in the twelve months to 30 June 2026: −$25.0M.

  • Shares outstanding: 65.0M.

  • Trailing P/E: −4.2×; forward P/E: −4.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Treace Medical Concepts, Inc. employs 450 people — $456K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

TMCI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
TMCITreace Medical Concepts, Inc.$253.0M
53
TLSITriSalus Life Sciences, Inc.$247.0M
32
LABStandard BioTools, Inc.$261.5M
26
QSIQuantum-Si, Inc.$262.9M
36
ELMDElectromed, Inc.$231.9M
92
INFUInfuSystem Holdings, Inc.$267.1M
100
MOBIMobia Medical, Inc.$283.2M
2

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Treace Medical Concepts, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TMCI news & analysis

Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

PRNewsWire · 26 Sept 2026negative

A law firm is encouraging Treace Medical Concepts, Inc. shareholders to contact them about potential breaches of fiduciary duties by company insiders. The firm states it would handle any matter on a contingent fee basis, with no out-of-pocket legal costs for shareholders.

Why it matters — The announcement signals a potential shareholder investigation or legal action against TMCI insiders, which TMCI watchers would monitor for possible governance or legal developments.

Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure

GlobeNewsWire · 17 Sept 2026positive

Treace Medical Concepts announced the presentation of results from three clinical studies at the American Orthopaedic Foot & Ankle Society Annual Meeting in Seattle, Washington. The presentations include data from the milestone 5-year ALIGN3D Lapiplasty study demonstrating sustained, positive outcomes, as well as the MTA3D Adductoplasty and SPRINT SpeedPlate clinical studies.

Why it matters — The 5-year ALIGN3D data showing sustained positive outcomes supports the evidence base for the company's flagship Lapiplasty procedure, which is central to Treace's business.

Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting

GlobeNewsWire · 15 Sept 2026positive

Treace Medical Concepts highlighted new product innovations and clinical data across its expanding foot and ankle portfolio at the 2026 AOFAS Annual Meeting. The company said the new product offerings extend its bunion market leadership and accelerate penetration into new foot and ankle market adjacencies.

Why it matters — TMCI watchers would care because the company is showcasing expanded product offerings and clinical data that position it to extend its leadership and enter new market segments within the foot and ankle space.

Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Treace Medical Concepts, Inc. (TMCI) published the transcript of its Q2 2026 earnings call, as covered by Seeking Alpha. The report identifies the source and subject matter of the call but provides no figures or details from the discussion.

Why it matters — TMCI watchers would care because the earnings call transcript is a primary source of information on the company's recent quarterly performance and management commentary.

Treace Medical Concepts Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026negative

Treace Medical Concepts reported second-quarter 2026 revenue of $45.4 million, down 4% from the prior-year period. The decline was attributed to lower procedure-kit sales to stocking distributors and a continued shift toward lower-priced minimally invasive products.

Why it matters — TMCI watchers would care because the company's reported revenue declined year over year due to distributor purchasing patterns and product-mix changes.

FAQ

Frequently asked questions about TMCI stock

What is the TMCI stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Treace Medical Concepts, Inc. have a median 12-month price target of $5, with estimates ranging from $4.5 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TMCI stock a buy right now?

Of the 5 analysts covering Treace Medical Concepts, Inc., 1 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Treace Medical Concepts, Inc. 53 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TMCI?

As at 8 Oct 2026, Treace Medical Concepts, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (85 of 100).

Will TMCI stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +29.0% from the last close, and Ticker Nerd's factor model ranks Treace Medical Concepts, Inc. 53 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TMCI stock forecast for 2030?

No analyst covering Treace Medical Concepts, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TMCI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.5 to $7 over the next 12 months.

How has TMCI stock performed over the past year?

Treace Medical Concepts, Inc. returned -37.1% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Treace Medical Concepts, Inc. do?

Treace Medical Concepts Inc. is a medical technology company focused on orthopedic solutions for foot and ankle care.

What is the latest news on TMCI?

The most recent item we track (PRNewsWire, 26 Sept 2026): "Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?". A law firm is encouraging Treace Medical Concepts, Inc. shareholders to contact them about potential breaches of fiduciary duties by company insiders. The firm states it would handle any matter on a contingent fee basis, with no out-of-pocket legal costs for shareholders.

Company

About Treace Medical Concepts, Inc.

Treace Medical Concepts Inc. is a medical technology company focused on orthopedic solutions for foot and ankle care. Its core offerings include surgical systems, instruments, implants, and biologic solutions designed for the treatment of bunion deformities and related midfoot conditions. The company’s product portfolio is centered on procedures that help surgeons address the underlying structure of hallux valgus, with systems such as Lapiplasty supporting three-dimensional bunion correction. Treace Medical Concepts serves orthopedic surgeons, podiatrists, ambulatory surgery centers, and other healthcare providers involved in foot and ankle surgery. Its products are used in commercial-stage clinical settings and are part of the broader medical devices market, where the company contributes specialized tools intended to improve procedural consistency and surgical workflow. Headquartered in Ponte Vedra Beach, Florida, Treace Medical Concepts operates as a focused player in the musculoskeletal device segment, with an emphasis on dedicated treatment solutions for bunion and midfoot procedures.

CEO Mr. John T. Treace · 450 employees · United States · https://www.treace.com